Business Wire

Optovue First to Release High Density OCT Angiography for Ophthalmology

Del

Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), is the first company to offer higher density OCTA imaging that provides significant improvement in resolution and peripheral visualization of vasculature in the eye. AngioVueHD Imaging, commercially released by Optovue today, provides OCTA scans with 73 percent more sampling points* and improves image resolution by approximately 33 percent over the existing field-of-view, enabling physicians to more closely assess the fine vasculature in the eye for changes that could indicate ocular disease.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170426005353/en/

AngioVueHD Montage automatically combines two high-density images in a 10x6 mm field-of-view. Images ...

AngioVueHD Montage automatically combines two high-density images in a 10x6 mm field-of-view. Images courtesy of Adil El Maftouhi, O.D., Lyon, France

According to Nadia Waheed, M.D., MPH, associate professor of Ophthalmology at Tufts Medical School and director of the Boston Image Reading Center, “The improved density of AngioVueHD provides the high resolution resembling that of 3x3 millimeter scans – the size we previously used to obtain the highest image quality – yet in a larger, 6x6 millimeter format. As a result, we have much greater image resolution for the 6x6 millimeter field-of-view, allowing for better assessment of pathologies characterized by large or oblique lesions.”

One of the major challenges of OCTA imaging is the limited region of the eye that can be visualized for assessing fine microvasculature. Currently, the standard field-of-view for the best image quality measures 3x3 millimeters. Optovue has significantly improved image quality in the 6x6 millimeter field-of-view with the AngioVueHD update to its AngioVue® Imaging option. The feedback from early clinical evaluators of the AngioVueHD enhancements suggests the new 6x6 millimeter OCTA scan enables the improved likelihood of detecting abnormalities and assessing fine microvasculature details that would typically extend beyond the central 3x3 millimeter region.

The company also released AngioVueHD Montage, which automatically combines two high-density images – one at the central macular region (the portion of the retina responsible for central, high-resolution color vision that is possible in good light), and the other centered at the optic disc (the entry point for the major blood vessels that supply the retina) – in a 10x6 millimeter field-of-view. The ability to automatically create the montage is useful for imaging vasculature in potential pathologies that may extend into the periphery of the imaging plane.

“Extending the AngioVueHD to include an automatic montage in an even wider 10x6 millimeter format will assist me in understanding lesions as they arise outside the macula,” continued Dr. Waheed.

“AngioVueHD will become the new gold standard in OCTA imaging and it will transform the way physicians use this technology to care for their patients,” said Jay Wei, founder and chief executive officer at Optovue. “Our AngioVue platform is already providing eye care professionals with a faster, non-invasive imaging technique that provides superior image quality of retinal and choroidal microvasculature. With the new, higher density image resolution in a larger field-of-view, we have raised the bar for OCTA imaging.”

About Optovue

Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercialization of high-speed OCT and OCTA technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. Optovue is the first company to develop and commercialize the pioneering OCTA technology. To date, there are over 225 peer-reviewed publications detailing the AngioVue Imaging technology and clinical applications. The company has installed over 11,000 products worldwide and employs over 170 people. For more information, visit www.optovue.com.

*73 percent more sampling points than current AngioVue 6x6 mm scan.

Contact information

for Optovue, Inc.
Amy Cook
amy@amcpublicrelations.net

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13Pressemelding

Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712

Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21Pressemelding

Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr

Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38Pressemelding

A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L

Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00Pressemelding

Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a

AML BitCoin Enters Phase II of ICO15.12.2017 09:00Pressemelding

NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom